Gilead Sciences (GILD.US) announced that it had struck a licensing agreement to produce the antiviral drug remdesivir in 127 countries, not including the US. The company’s will work with five generic drugmakers to produce the potential drug for coronavirus. Among them is Mylan (MYL.US), which is the world's largest producer of generic drugs.

Gilead Sciences (GILD.US) shares rose 1.96% in pre-market trading. If positive mood persists, then resistance at $86.16 per share may be tested. Source: xStation5
Economic calendar: NFP data and US oil inventory report 💡
Daily summary: Weak US data drags markets down, precious metals under pressure again!
Datadog in Top Form: Record Q4 and Strong Outlook for 2026
US Open: Wall Street rises despite weak retail sales